Zobrazeno 1 - 10
of 72
pro vyhledávání: '"M C, Bissery"'
Autor:
M. C. Bissery
Publikováno v:
Current Pharmaceutical Design. 7:1251-1257
Paclitaxel and docetaxel are two key molecules in the treatment of a variety of cancers with major impact in the treatment of breast, lung and ovarian cancers. A number of taxoids have then been synthesized in an effort to improve some of the feature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1b85ff271b2bda484d52b61c5340bff
https://doi.org/10.2174/1381612013397465
https://doi.org/10.2174/1381612013397465
Publikováno v:
British Journal of Cancer
We have studied the state of microtubule associated protein 2 (MAP2) in the pancreatic ductal adenocarcinomas P03 and P02 (sensitive and refractory to docetaxel respectively) since they express the corresponding mRNA and MAP2-related peptides. Immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::592a3d39ddb4c04754556f812f542313
https://doi.org/10.1054/bjoc.2000.1294
https://doi.org/10.1054/bjoc.2000.1294
Autor:
François Lavelle, M.‐C. Bissery, Suzy Cros, J. Renault, Michel Baron, Sylviane Giorgi-Renault, Patricia Gebel-Servolles, Ghanem Atassi, C. Paoletti
Publikováno v:
ChemInform. 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad64fdd905487416879ce94f00aab875
https://doi.org/10.1002/chin.199122166
https://doi.org/10.1002/chin.199122166
Publikováno v:
Pathologie-biologie. 51(4)
We previously demonstrated a circadian rhythm in response to docetaxel chemotherapy in C3H/HeN mice bearing MA13/C mammary adenocarcinoma. We investigated the relation between this rhythm and the expression of BCL-2 in bone marrow and in tumor tissue
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3b75f4b30c723e035b1c9ea2fd1d3f06
https://pubmed.ncbi.nlm.nih.gov/12852995
https://pubmed.ncbi.nlm.nih.gov/12852995
Autor:
Mario Campone, P. Fumoleau, M.-C. Bissery, Geneviève Perrocheau, N. Azli, Valérie Delecroix, A. Riva, J. P. Louboutin, R. Deporte-Fety, L. Vernillet, O. Borg-Olivier
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(7)
Summary Background and purpose: Anthracycline-containing regimens are widely used in advanced breast cancer. However, there is a need for new, non-anthracycline regimens that are active in patients for whom anthracyclines are contraindicated. The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727d5468cd7f773f1645851e3cdf2dbd
https://pubmed.ncbi.nlm.nih.gov/11521794
https://pubmed.ncbi.nlm.nih.gov/11521794
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice
Publikováno v:
British Journal of Cancer
Docetaxel is a new taxoid with clinical activity in breast and lung cancer. Using docetaxel-sensitive and -refractory mammary and pancreatic murine tumours, as well as human-derived neoplasms, we investigated if a determinant of docetaxel sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b609658366ad8af3bc5dab10d9dfc40d
https://pubmed.ncbi.nlm.nih.gov/9764577
https://pubmed.ncbi.nlm.nih.gov/9764577
Publikováno v:
Seminars in oncology. 23(1 Suppl 3)
CPT-11 (irinotecan) is a water-soluble analogue of camptothecin (CPT), an antitumor drug extracted from the Chinese tree Camptotheca acuminata. SN-38 is an active metabolite of CPT-11 that contributes significantly to its activity. The antitumor effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4400f4d9155b4c4c450df4ab151ba1d5
https://pubmed.ncbi.nlm.nih.gov/8633248
https://pubmed.ncbi.nlm.nih.gov/8633248
Publikováno v:
Seminars in oncology. 22(6 Suppl 13)
Docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) is a new taxoid currently being studied in phase II and III clinical trials worldwide, with promising activity in breast cancer. Docetaxel was evaluated as a single agent against against seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::478e481594f81394ab00a0a79722d48d
https://pubmed.ncbi.nlm.nih.gov/8604451
https://pubmed.ncbi.nlm.nih.gov/8604451
Publikováno v:
Anti-cancer drug design. 10(4)
In order to study the structure-activity relationships in the series of new intercalating polycyclic agents, 1-amino-substituted pyrido[3,4-b]quinoxalines, benzo[f]pyrido[4,3-b]quinoxaline derivatives bearing a dibasic side chain and their benzo[f]py
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::281345fa1ad307849887c6460c1b887c
https://pubmed.ncbi.nlm.nih.gov/7786395
https://pubmed.ncbi.nlm.nih.gov/7786395
Publikováno v:
Seminars in oncology. 22(2 Suppl 4)
Progress in cancer chemotherapy has been made owing to the discovery and development of drugs that have new structures, new mechanisms of action, and high levels of experimental antitumor activity. Docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3ea21f4381e074f0e329cef5dc2cfdd5
https://pubmed.ncbi.nlm.nih.gov/7740328
https://pubmed.ncbi.nlm.nih.gov/7740328